Antimycobacterial Susceptibility Testing of Nontuberculous Mycobacteria-Reference-Cited by-同舟云学术

Antimycobacterial Susceptibility Testing of Nontuberculous Mycobacteria

Published:2019-10 Issue:10 Volume:57 Page:
ISSN:0095-1137
Container-title:Journal of Clinical Microbiology
language:en
Short-container-title:J Clin Microbiol

Author:

Brown-Elliott Barbara A.¹,Woods Gail L.²

Affiliation:

1. Mycobacteria/Nocardia Research Laboratory, University of Texas Health Science Center at Tyler, Tyler, Texas, USA

2. Pathology Department, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA

Abstract

Recommendations for first-line and second-line drug testing and organism group, specific methodologies, and reporting recommendations have been addressed by the Clinical and Laboratory Standards Institute (CLSI) and are important in the selection of appropriate antimicrobial treatment regimens for nontuberculous mycobacteria (NTM) disease.

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Link

https://journals.asm.org/doi/pdf/10.1128/JCM.00834-19

Reference31 articles.

1. Clinical and Laboratory Standards Institute. 2011. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard, 2nd ed. CLSI document M24-A2. Clinical and Laboratory Standards Institute, Wayne, PA.

2. Clinical and Laboratory Standards Institute. 2018. Susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomycetes, 3rd ed, CLSI standard document M24. Clinical and Laboratory Standards Institute, Wayne, PA.

3. Clinical and Laboratory Standards Institute. 2018. Performance standards for susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomycetes, 1st ed. CLSI document M62. Clinical and Laboratory Standards Institute, Wayne, PA.

4. Clinical and Laboratory Standards Institute. 2018. Laboratory detection and identification of mycobacteria. CLSI guideline M48. Clinical and Laboratory Standards Institute, Wayne, PA.

5. An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prevalence of antibiotic resistance in clinical isolates of M. kansasii : a systematic review and meta-analysis;Expert Review of Anti-infective Therapy;2024-01-31

2. 2,3,5-triphenyl tetrazolium chloride as colorimetric indicator for drug susceptibility testing against nontuberculous mycobacteria;Diagnostic Microbiology and Infectious Disease;2024-01

3. Analyse pharmacologique du traitement des pneumopathies à Mycobacterium abscessus;Revue des Maladies Respiratoires;2024-01

4. Management Challenges of Extrapulmonary Nontuberculous Mycobacterial Infection: A Single-Center Case Series and Literature Review;Pathogens;2023-12-21

5. Differential Immune Responses and Underlying Mechanisms of Metabolic Reprogramming in Smooth and Rough Variants of Mycobacterium peregrinum Infections;Pathogens;2023-12-13